Stocks and Investing
Stocks and Investing
Fri, March 12, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, March 11, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tiago Fauth Maintained (ASND) at Buy with Decreased Target to $176 on, Mar 11th, 2021
Tiago Fauth of Credit Suisse, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Decreased Target from $178 to $176 on, Mar 11th, 2021.
Tiago has made no other calls on ASND in the last 4 months.
There are 2 other peers that have a rating on ASND. Out of the 2 peers that are also analyzing ASND, 0 agree with Tiago's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Tiago
- David Lebovitz of "Morgan Stanley" Maintained at Buy with Increased Target to $199 on, Friday, November 13th, 2020
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $191 on, Thursday, November 12th, 2020
Contributing Sources